Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.051 CHF | -13.56% | -11.46% | +24.39% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+24.39% | 3.79M | |
-3.45% | 87.17B | |
+1.97% | 40.1B | |
+56.59% | 25.12B | |
-14.82% | 15.59B | |
-8.82% | 12B | |
-16.29% | 11.8B | |
-41.58% | 11.8B | |
+6.14% | 8.81B | |
-10.76% | 8.24B |
- Stock Market
- Equities
- POLN Stock
- News Spexis AG
- Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis